Scale -


  • Revenue is 611 Rs Cr; Continuous Growth over 3 years
  • Ebitda is 112 Rs Cr; Continuous Growth over 3 years
  • PBT is 16.46 Rs Cr; Annual Decline is -37 %; 5 Year CAGR is -25 %
  • PAT is 15.77 Rs Cr; Annual Decline is -60 %; 5 Year CAGR is -31 %

Profitability -


  • PAT Margin is 2.58 %; Annual Decline is -65 %; 5 Year CAGR is -30 %

Return -


  • Asset Turnover is 70 %; Continuous Growth over 3 years
  • ROA is 1.7 %; Annual Decline is -64 %; 5 Year CAGR is -36 %
  • ROE is 2.95 %; Annual Decline is -65 %; 5 Year CAGR is -39 %

Efficiency -


  • Operating cash flow is 58.08 Rs Cr; Annual Growth is 169 %; 5 Year CAGR is 203 %
  • Current Ratio is 1.98; Continuous Growth over 3 years

Solvancy -


  • Contingent Liabilities is 23.56 Rs Cr; Annual Decline is -32 %
  • Debt/Equity is 0.44; Continuous Decline over 3 years; in Top Quartile

Quality -


  • Operating cashflow/ebitda is 52 %; Annual Growth is 144 %; 5 Year CAGR is 208 %
  • Operating cashflow/PAT is 368 %; Annual Growth is 573 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 342 %
  • Exceptional Items/PBT is -115 %; Continuous Decline over 3 years; in Bottom Quartile
  • Current Tax/PAT is 0 %; in Bottom Quartile
  • Change in Inventories/Total Expenses is 2 %; Annual Growth is 146 %; in Top Quartile
  • Other Expenses/Total Expenses is 23 %; Continuous Growth over 3 years; 5 Year CAGR is 54 %

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem


Sector
Major Subsidiaries/Associates
Key Clients

Products


Products
Product details

Operations


Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
Bajaj Healthcare Ltd Estimates – NSE:BAJAJHCARE
NCLT Approves Bajaj Healthcare's Acquisition of Genrx Pharmaceuticals as Going Concern
Bajaj Healthcare Q2FY27 Results: Net profit up 26.9% YoY to ?14.1 crore
Bajaj Healthcare Reports Q2 Standalone Net Profit Of ?14.1 Crore Vs ?11.1 Crore YoY
NCLT Mumbai Allows Bajaj Healthcare To Acquire GENRX Pharmaceuticals
Bajaj Healthcare secures NCLT approval for Genrx acquisition